



SESSION 3: SCIENCE, DATA, EVIDENCE FOR DECISION- MAKING

The AOP Framework Experience

Dr. Carlie A. LaLone, US Environmental Protection Agency

Dr. Magdalini Sachana, OECD

The views expressed in this poster are those of the authors and do not necessarily reflect the views or policies of the U.S. EPA.




Challenges in chemical safety assessment

01

High number of untested chemicals

To close this data gap with the current approach that relies almost completely on animal testing is not achievable



02

Research innovation

Development of cutting edge cellular models, computational methods, and technologies could advance chemical safety assessment

03


Storage and dissemination of mechanistic knowledge

Currently through peer-reviewed journals, text books, reports, laboratory notebooks, agency archives, institutional and government databases





Countries are improving their legislation to assess more chemicals in a shorter time frame



CHEMICALS
MANAGEMENT
PLAN

PLAN DE
GESTION DES
PRODUITS CHIMIQUES



Transformation in Standard Toxicity Testing




5000 animals / chemical



Test duration
30 – 720 days



Costs
€2,000 - €2,000,000




Avian reproduction study (OECD TG 206)
Animals: > 200
Test duration: > 30 weeks
Cost: > \$250,000

Toxicity Testing in the 21st Century:


- *In vitro* and *in silico* methods
 - Pathway-based approaches
 - Focus on disturbance of the biological pathway
 - Predictive of the observable toxic effects

**New Approach Methods
(NAMs)**



High throughput toxicology

- > 600 in vitro assays
- days
- ≈ \$ 20,000



- **Validation of NAMs for confidence in decision-making**
- **Diverse data streams need integration**



Stages of AOP Development

Stages of AOP Development	Characteristics	Increasing
Putative AOPs:	<u>Hypothesized</u> set of KEs and KERs primarily <u>supported</u> by <u>biological plausibility</u> and/or <u>statistical inference</u>	• Depth of evidence /understanding
Formal AOPs:	Include assembly and evaluation of the supporting <u>weight of evidence</u> – developed in AOP knowledgebase in accordance with internationally-harmonized <u>OECD guidance</u>	• Transparency /defensibility
Quantitative AOPs:	Supported by <u>quantitative relationships</u> and/or <u>computational models</u> that allow <u>quantitative translation</u> of key event measurements into predicted probability or severity of adverse outcome	• Quantitative precision
		• Cost • Data needs • Time

- All stages have potential utility
- Level of development desired/required depends on the application




Evaluating the Strength of Evidence for an AOP

1. Strength of association
2. Consistency
3. Specificity of association
4. Temporality
5. Biological gradient
6. Plausibility
7. Coherence
8. Experimental evidence
9. Analogy






Detailed description of the AOP development process





The virtuous circle of collaboration





Application of the AOP Framework

- Enhance use of mechanistic data in regulatory decision-making
- Support hypothesis-driven testing - target in vivo testing on endpoints of concern
- Inform appropriate cross-species extrapolation & focus testing on species, life-stages, taxa of concern
- Aid a strategic, knowledge-driven approach to evaluating complex mixtures
- Identify critical knowledge & evidence gaps that impede application



CASESTUDIES




From IATA to DAs

IATA	Defined Approaches
Designed in response to problem formulation	Designed to address pre-defined endpoint/prediction
Inputs are defined by user	Defined information sources
Sequence of input, next steps, decision context defined by user	Sequence defined and next steps are rule-based
Expert judgement for weighting data, interpreting data	Fixed data interpretation procedure
Conclusion may be open to interpretation	Regulatory conclusion is clear

- Defined approaches:
 - Remove expert judgement
 - Are **not flexible** and **are suitable** for harmonisation
- **OECD has the first approved Defined Approach that would be covered by mutual acceptance of data (MAD)**




AOP for Skin Sensitization





Test Methods Mapped to AOP





OECD Defined Approaches SS Guideline

- Extensive curation efforts undertaken to build reference databases (LLNA, Human)
- Applicability Domain and DA Confidence defined
- Final draft guideline was approved on April 2021
- DA GL will meet regulatory requirements of:
 - DAs that discriminate skin sensitisers from nonsensitisers
 - DAs that discriminate strong from moderate/weak sensitisers (GHS potency categories)
- Future work will cover DAs that address regulatory needs of quantitative risk assessment




DNT *In Vitro* Battery


NPC1




NPC2a,b,c




NPC3




NPC4



NPC5



UKN2




UKN4/5




r/hNNF Assay

Neuronal Network Formation




V Viability

C Cytotoxicity






Key neurodevelopmental processes and DNT *In Vitro* Battery






Key neurodevelopmental processes in AOPs





Gap analysis






AOP informed IATA for DNT

Step 1. Definition of the Problem formulation. Definition of the methods. Establishment of a Protocol.


Developmental Neurotoxicity (DNT) Hazard characterization of Deltamethrin

Step 2. Systematic data collection and appraisal

DNT: any adverse effect on the normal development of nervous system structures and/or function, predefined by different endpoints in vivo, in vitro and human.



Step 3. Data integration and analysis. AOP framework



Step 4. Filling the data gap. In vitro testing battery integration.

IVB appraisal and evidence synthesis

Step 5. Data analysis and interpretation in the light of the uncertainty analysis



Step 6. Probabilistic assessment of the IATA-AOP Network.

Bayesian Network approach to assess the KERs
Joint Probability distribution of the AOP.

IATA workflow

Uncertainty Analysis

Hazard identification using a probabilistic approach.
Hazard characterization by Expert Knowledge elicitation

Key words:

- Problem formulation
- Stressor based AOP
- Evidence based approach
- Systematic approach
- Uncertainty analysis

Stressor-based putative AOP Network

MIE

Cellular response

Organ response

Organism response

Neuro developmental cells (human, rodents...)

rodents

MiE2
Binding to Ryanodine receptors

Prob > 0.66
(0.01 – 0.03] uM

KE7
Disruption of intracellular Ca channel kinetics.

Prob > 0.66
(0.01 – 0.03] uM

MiE1
Binding to VGSC

Prob > 0.66
(0.01 – 1] uM

KE1
Disruption of sodium channel gate kinetics

Prob > 0.66
[0.01-1] uM

KE2

Disruption of action potential

Prob > 0.66
[0.01-1] uM

KE3

Disruption of axon terminal depolarization; changes in neurotransmitter release

Prob > 0.66
(0.25-9] mg/kg/day

KE4

Altered neuronal network function

Prob > 0.66
(0.04-5] uM
(97%)

AO

Impairment behavioural function (sensory motor reflex and learning)

Prob > 0.66
(0.25-7.25] mg/kg bw/d
(96%)

KE5 Decreased oligodendrocyte differentiation

Prob > 0.66 / 0.5 [0.25-0.76] uM

KE9 Hypomyelination

KER8

KE6. Altered of Sodium kinetics in microglia

Prob > 0.66/ 1 uM

KER9

KER7

KER10

KER11

KER1

KER2

KER3

KER4

KER5

KER6


KER7

KER9




IATA-related endocrine projects: Estrogen receptor active chemicals

- IATA case study project
 - Led US
 - Considered with a defined approach
 - Combines results from ≥ 4 in vitro assays to predict the rodent in vivo uterotrophic response





Simplified Non-genotoxic carcinogenicity AOP flow



Ongoing work of the NGTxC expert group – do not cite or quote




AOP conceptual framework, a useful tool for Human Health Risk Assessment

- Contextualise the NAMs
- Understanding what are you testing for
- Avoid additional testing
- Identify data gaps and perform targeted testing
- Use human data rather than rodent data in the process of hazard characterization



Pollinator Health



Identification of knowledge gaps
Multiple contributors weaken the colony
Nodes impacted by multiple stressors

Understanding
Contributed to
Mitigation Policy

U.S. ENVIRONMENTAL PROTECTION AGENCY'S POLICY TO MITIGATE THE ACUTE RISK TO BEES FROM PESTICIDE PRODUCTS

U.S. Environmental Protection Agency

Office of Pesticide Programs

January 12, 2017



Developmental and Reproductive Toxicology/Endocrine Activity


Opportunity to replace with high throughput in vitro screening



Thyroid AOP Network

- identification of MIE space to cover in a HTS battery


- Median estimated cost: \$75,000 [OECD 2012; ENV/JM/MONO(2012)22]
- Animal use: \approx 320 tadpoles per test
- Time: 21 d test; histology; husbandry and staging





Directly translating mechanistic data directly into predicted adverse outcomes for relevant exposure scenario

Quantitative Prediction of Reproductive/Population Effects





Review Challenges to Uptake of the AOP Framework

- Not enough AOPs to adequately cover biological space (example)
- Time consuming as information is spread in many journals
- Additional quality evaluation is required
- Scarce regulatory feedback on application of AOPs